Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
520.36 USD | +0.34% |
|
+7.74% | -26.93% |
Capitalization | 54.8B 47.72B 44.92B 40.46B 74.91B 4,683B 84.08B 523B 203B 2,144B 206B 201B 7,926B | P/E ratio 2025 * |
17.5x | P/E ratio 2026 * | 14.8x |
---|---|---|---|---|---|
Enterprise value | 45.54B 39.65B 37.33B 33.62B 62.25B 3,891B 69.87B 435B 168B 1,782B 171B 167B 6,587B | EV / Sales 2025 * |
3.38x | EV / Sales 2026 * | 3.07x |
Free-Float |
77.36% | Yield 2025 * |
0.55% | Yield 2026 * | 0.58% |
More valuation ratios
* Estimated data
More news
Last Transcript: Regeneron Pharmaceuticals, Inc.
More recommendations
More press releases
More news
1 day | -0.94% | ||
1 week | +6.94% | ||
Current month | +5.78% | ||
1 month | -1.74% | ||
3 months | -27.79% | ||
6 months | -32.91% | ||
Current year | -27.20% |
1 week | 485 | ![]() | 529.99 |
1 month | 476.49 | ![]() | 617.52 |
Current year | 476.49 | ![]() | 748.29 |
1 year | 476.49 | ![]() | 1,211.2 |
3 years | 476.49 | ![]() | 1,211.2 |
5 years | 441 | ![]() | 1,211.2 |
10 years | 271.37 | ![]() | 1,211.2 |
Manager | Title | Age | Since |
---|---|---|---|
President | 65 | 2000-12-31 | |
Chief Executive Officer | 72 | 1988-01-07 | |
Director of Finance/CFO | 54 | 2024-02-04 |
Director | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 2023-06-08 | |
Michael Brown
BRD | Director/Board Member | 84 | 1991-05-31 |
Joseph Goldstein
BRD | Director/Board Member | 84 | 1991-05-31 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.94% | +6.94% | -48.68% | -9.31% | 54.8B | ||
-0.31% | -0.31% | +43.99% | +62.15% | 35.51B | ||
-0.38% | +1.60% | +65.46% | +77.94% | 33.43B | ||
+0.23% | -0.11% | +53.20% | -36.74% | 26.04B | ||
-1.34% | -5.11% | +6.74% | -26.69% | 25.35B | ||
+7.75% | +32.96% | +58.36% | +436.29% | 17.85B | ||
-11.32% | +0.10% | +159.68% | +1,943.84% | 14.54B | ||
-0.70% | +3.20% | -21.62% | -28.15% | 14.08B | ||
+4.13% | +11.65% | +121.69% | -57.23% | 13.81B | ||
-2.56% | -1.87% | +88.06% | +128.39% | 11.3B | ||
Average | -1.47% | +4.41% | +52.69% | +249.05% | 24.67B | |
Weighted average by Cap. | -1.12% | +4.09% | +33.94% | +158.02% |
2025 * | 2026 * | |
---|---|---|
Net sales | 13.47B 11.73B 11.05B 9.95B 18.42B 1,151B 20.67B 129B 49.84B 527B 50.54B 49.49B 1,949B | 14.3B 12.45B 11.72B 10.55B 19.54B 1,222B 21.93B 137B 52.87B 559B 53.62B 52.5B 2,068B |
Net income | 3.17B 2.76B 2.6B 2.34B 4.34B 271B 4.87B 30.3B 11.73B 124B 11.9B 11.65B 459B | 3.56B 3.1B 2.92B 2.63B 4.87B 305B 5.47B 34.05B 13.18B 139B 13.37B 13.09B 516B |
Net Debt | -9.26B -8.06B -7.59B -6.84B -12.66B -791B -14.21B -88.46B -34.25B -362B -34.74B -34.01B -1,340B | -10.88B -9.48B -8.92B -8.04B -14.88B -930B -16.7B -104B -40.26B -426B -40.83B -39.98B -1,574B |
More financial data
* Estimated data
Employees
15,158
Calendar
Jun. 13
- Annual General Meeting
Date | Price | Change | Volume |
---|---|---|---|
25-06-12 | 520.48 $ | +0.36% | 253,409 |
25-06-11 | 518.60 $ | -0.94% | 963,105 |
25-06-10 | 523.53 $ | +1.15% | 1,175,230 |
25-06-09 | 517.60 $ | +4.94% | 1,983,125 |
25-06-06 | 493.22 $ | +2.10% | 1,497,999 |
Delayed Quote Nasdaq, June 11, 2025 at 04:00 pm EDT
More quotesSell
Buy

Mean consensus
BUY
Number of Analysts
26
Last Close Price
518.60USD
Average target price
727.21USD
Spread / Average Target
+40.23%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions